SCHEMBL6232625

SCHEMBL6232625

C=CC(=O)NC1CC2CCC1C2

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 1/20 0.54
SMN1; SMN2 Q16637 1/20 0.54
EPHX2 P34913 4/20 0.53
EPHX1 P07099 1/20 0.51
MAPK1 P28482 1/20 0.51
ALDH1A1 P00352 3/20 0.47
RAB9A P51151 1/20 0.46
SIGMAR1 Q99720 4/20 0.45
TAS1R3 Q7RTX0 1/20 0.45
TAS1R1 Q7RTX1 1/20 0.45
TAS1R2 Q8TE23 1/20 0.45
GRIN2D O15399 2/20 0.44
GRIN3B O60391 2/20 0.44
GRIN1 Q05586 2/20 0.44
GRIN2A Q12879 2/20 0.44
GRIN2B Q13224 2/20 0.44
GRIN2C Q14957 2/20 0.44
GRIN3A Q8TCU5 2/20 0.44
MAPT P10636 1/20 0.44
GAA P10253 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10352170 0.80 HPGD (0.37) HPGDSMN1; SMN2EPHX2EPHX1MAPK1
SCHEMBL13951142 0.79 HPGD (0.37) HPGDSMN1; SMN2EPHX2EPHX1MAPK1
SCHEMBL3071717 0.78 EPHX2 (0.61) HPGDSMN1; SMN2EPHX2EPHX1MAPK1
SCHEMBL3068813 0.78 EPHX1 (0.76) HPGDSMN1; SMN2EPHX2EPHX1MAPK1
SCHEMBL3087394 0.77 HPGD (0.57) HPGDSMN1; SMN2EPHX2EPHX1MAPK1
SCHEMBL4461499 0.76 EPHX2 (0.59) HPGDSMN1; SMN2EPHX2EPHX1MAPK1
SCHEMBL15655475 0.76 EPHX2 (0.59) HPGDSMN1; SMN2EPHX2EPHX1MAPK1
SCHEMBL15655476 0.76 EPHX2 (0.59) HPGDSMN1; SMN2EPHX2EPHX1MAPK1
SCHEMBL26089624 0.76 EPHX2 (0.59) HPGDSMN1; SMN2EPHX2EPHX1MAPK1
SCHEMBL15655473 0.76 EPHX2 (0.59) HPGDSMN1; SMN2EPHX2EPHX1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113164495-B Covalent targeting of E3 ligases 加利福尼亚大学董事会 2025-04-22 CN disclosed
US-20250120982-A1 COVALENT TARGETING OF E3 LIGASES THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2025-04-17 US disclosed
US-12161648-B2 Covalent targeting of E3 ligases THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2024-12-10 US disclosed
US-20210369731-A1 COVALENT TARGETING OF E3 LIGASES THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2021-12-02 US disclosed
US-20210369731-A1 COVALENT TARGETING OF E3 LIGASES THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2021-12-02 US disclosed
EP-3863642-A1 COVALENT TARGETING OF E3 LIGASES The Regents of the University of California (US) 2021-08-18 EP disclosed
CN-113164495-A Covalent targeting of E3 ligase 加利福尼亚大学董事会 2021-07-23 CN disclosed
US-8524116-B2 Multilayer sheet containing optically anisotropic layer containing liquid crystal compound and cellulose ester with polymer FUJIFILM CORPORATION (JP) 2013-09-03 US disclosed
US-8524116-B2 Multilayer sheet containing optically anisotropic layer containing liquid crystal compound and cellulose ester with polymer FUJIFILM CORPORATION (JP) 2013-09-03 US disclosed
US-8501331-B2 Binder composition for magnetic recording medium and magnetic recording medium FUJIFILM CORPORATION (JP) 2013-08-06 US disclosed
EP-0379305-B1 Low odor adhesive compositions MINNESOTA MINING & MFG (US) 1994-05-11 EP disclosed
EP-0572900-A2 Coating and its use in a process for preparing multilayer coatings Herberts Gesellschaft mit beschränkter Haftung (DE) 1993-12-08 EP disclosed
US-5244899-A Azabicycloalkyl and azatricycloalkyl amides used to treat inflammation, allergy, asthma and skin disorders G. D. SEARLE AND CO. (US) 1993-09-14 US disclosed
US-5198435-A Antiinflammatory, antiallergen G. D. SEARLE & CO. (US) 1993-03-30 US disclosed
US-5157053-A Bicycloalky, tricycloalkyl, azabicycloalkyl, and azatricycloalkyl thio amides used to treat inflammation, allergy, asthma and skin disorders G. D. SEARLE & CO. (US) 1992-10-20 US disclosed
US-5019597-A Antiinflammatory Agents, Antiallergens G. D. SEARLE & CO. (US) 1991-05-28 US disclosed
US-4945006-A UNSATURATED CYCLIC AMIDES, ANAEROBIC PROCESS MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1990-07-31 US disclosed
EP-0379305-A1 Low odor adhesive compositions MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1990-07-25 EP disclosed
EP-0190684-B1 BICYCLOALKYL, TRICYCLOALKYL, AZABICYCLOALKYL AND AZATRICYCLOALKYL AMIDES G.D. Searle & Co. (US) 1990-07-25 EP disclosed
EP-0190684-A2 Bicycloalkyl, tricycloalkyl, azabicycloalkyl and azatricycloalkyl amides G.D. Searle & Co. (US) 1986-08-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12161648-B2 Covalent targeting of E3 ligases RNF114, RNF4, RNF168 HPGD 4624/4885SMN1; SMN2 1834/4885EPHX2 4228/4885
US-20210369731-A1 COVALENT TARGETING OF E3 LIGASES RNF114, RNF4, RNF168 HPGD 4624/4885SMN1; SMN2 1834/4885EPHX2 4228/4885
US-20250120982-A1 COVALENT TARGETING OF E3 LIGASES STUB1, XIAP, RBX1 HPGD 4097/4885SMN1; SMN2 2872/4885EPHX2 2230/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.